Nuvation Bio Inc (NUVB) Stock Price, Quote & News

Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 208 6102

Website: www.nuvationbio.com

Address:

1500 Broadway, Suite 1401, New York, United States

JanetBSmellin Feb. 4 at 12:39 AM

$NUVB Drew this channel months ago. 😁😁😁

0 · Reply

Night_Owl_Biotech Feb. 3 at 10:52 PM

$NUVB Attached is a simple graph of NUVB's share price since 1/1/2025. Ibtrozi was approved 6/11/25. We're simply curious if NUVB investors sense the "fall" in NUVB's share price since releasing Q42025 sales is over? Sagard invested $150MM in exchange for a 5.5% royalty (roughly a $2.7B valuation...as a royalty) in addition to providing a traditional loan. This is not investment advice.

1 · Reply

JanetBSmellin Feb. 3 at 9:49 PM

$NUVB Wow! Lung cancer is so screwed.

0 · Reply

Incognito_21 Feb. 3 at 6:59 PM

$NUVB let’s do it again and finish strong today !

0 · Reply

Gabgoat Feb. 3 at 4:45 PM

$APLD I am really hesitating of full porting my 20k portfolio in this and $NUVB like 15k in this and 5k in NUVB bcz these a wild studs

0 · Reply

JuggernautRaider Feb. 3 at 2:56 PM

$NUVB $VRDN two strong biotechs 💪

0 · Reply

AlejandroDeGante Feb. 3 at 1:54 PM

$NUVB

0 · Reply

Night2 Feb. 3 at 6:45 AM

$NUVB

0 · Reply

Incognito_21 Feb. 2 at 7:51 PM

$NUVB Hoping for a big finish today!

1 · Reply

Hero07 Feb. 2 at 7:27 PM

$NUVB this will fly to $9 before we know it. Its a massive SPRING....for the SPRING. June 7th target!

0 · Reply

Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy

Jan 22, 2026, 10:26 AM EST - 12 days ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 13, 2026, 10:16 PM EST - 21 days ago

Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:00 AM EST - 22 days ago

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 22 days ago

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Jan 6, 2026, 4:05 PM EST - 4 weeks ago

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 6, 2025, 10:40 PM EST - 2 months ago

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

Dec 3, 2025, 11:53 AM EST - 2 months ago

Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 8:00 AM EST - 2 months ago

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

Nov 29, 2025, 4:37 AM EST - 2 months ago

Nuvation Bio: A Strong Company Now Fairly Priced

Nov 26, 2025, 4:05 PM EST - 2 months ago

Nuvation Bio to Participate in Upcoming Investor Conferences

Nov 21, 2025, 10:13 PM EST - 2 months ago

Nuvation Bio Inc. (NUVB) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 7, 2025, 5:23 PM EST - 3 months ago

Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case

Nov 3, 2025, 9:46 PM EST - 3 months ago

Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:05 PM EST - 3 months ago

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 7:30 AM EDT - 3 months ago

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Oct 20, 2025, 4:05 PM EDT - 3 months ago

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Sep 30, 2025, 7:30 AM EDT - 4 months ago

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Sep 29, 2025, 1:15 PM EDT - 4 months ago

3 Of My Favorite Biotech Stocks Under $10

DVAX FOLD MRNA PFE

Sep 19, 2025, 7:30 AM EDT - 4 months ago

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Sep 15, 2025, 12:27 PM EDT - 5 months ago

Nuvation Bio: A Rare Gem In The Risky Biotech Space

Sep 7, 2025, 6:00 AM EDT - 5 months ago

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Sep 5, 2025, 10:39 AM EDT - 5 months ago

Top 2 Health Care Stocks That May Plunge This Month

ESPR

Aug 28, 2025, 12:16 PM EDT - 5 months ago

Nuvation Bio: What To Expect From IBTROZI Launch?

Aug 7, 2025, 7:30 AM EDT - 6 months ago

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 8:00 AM EDT - 6 months ago

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Jul 24, 2025, 4:05 PM EDT - 6 months ago

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 8 months ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Jun 16, 2025, 7:30 AM EDT - 8 months ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Jun 11, 2025, 1:45 PM EDT - 8 months ago

US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025, 1:20 PM EDT - 8 months ago

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 21, 2025, 4:05 PM EDT - 9 months ago

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 13, 2025, 4:05 PM EDT - 9 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 11, 2025, 10:05 PM EDT - 9 months ago

Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 9 months ago

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 9:07 AM EDT - 9 months ago

Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes

May 1, 2025, 4:05 PM EDT - 9 months ago

Nuvation Bio to Present at The Citizens Life Sciences Conference

Apr 22, 2025, 4:05 PM EDT - 10 months ago

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Mar 25, 2025, 4:45 PM EDT - 11 months ago

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 8:00 AM EDT - 11 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Mar 6, 2025, 4:30 PM EST - 11 months ago

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:35 AM EST - 1 year ago

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Feb 24, 2025, 8:00 AM EST - 1 year ago

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 1:49 PM EST - 1 year ago

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Feb 13, 2025, 5:09 PM EST - 1 year ago

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Feb 3, 2025, 8:00 AM EST - 1 year ago

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 6, 2025, 4:05 PM EST - 1 year ago

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 1 year ago

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 2, 2025, 7:00 PM EST - 1 year ago

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

JanetBSmellin Feb. 4 at 12:39 AM

$NUVB Drew this channel months ago. 😁😁😁

0 · Reply

Night_Owl_Biotech Feb. 3 at 10:52 PM

1 · Reply

JanetBSmellin Feb. 3 at 9:49 PM

$NUVB Wow! Lung cancer is so screwed.

0 · Reply

Incognito_21 Feb. 3 at 6:59 PM

$NUVB let’s do it again and finish strong today !

0 · Reply

Gabgoat Feb. 3 at 4:45 PM

$APLD I am really hesitating of full porting my 20k portfolio in this and $NUVB like 15k in this and 5k in NUVB bcz these a wild studs

0 · Reply

JuggernautRaider Feb. 3 at 2:56 PM

$NUVB $VRDN two strong biotechs 💪

0 · Reply

AlejandroDeGante Feb. 3 at 1:54 PM

$NUVB

0 · Reply

Night2 Feb. 3 at 6:45 AM

$NUVB

0 · Reply

Incognito_21 Feb. 2 at 7:51 PM

$NUVB Hoping for a big finish today!

1 · Reply

Hero07 Feb. 2 at 7:27 PM

$NUVB this will fly to $9 before we know it. Its a massive SPRING....for the SPRING. June 7th target!

0 · Reply

Shagg85 Feb. 2 at 2:06 PM

$NUVB let’s get er Nuvation bio. F**K cancer

1 · Reply

cled Feb. 2 at 9:48 AM

$NUVB

0 · Reply

njbugatti Feb. 1 at 7:47 PM

$NUVB Gross vs Net product revs - looking at Q3 and prelim Q4 metrics, it appears NUVB is selling Ibtrozi for $30K gross and $25K net per month. Someone with more expertise….are 15% typical discounts for industry/cancer drug companies? Are these variable discounts volume based or how does NUVB structure the discounts? Just curious. Thank you.

1 · Reply

SNOB_ORDER Jan. 31 at 11:11 AM

$NUVB TF weekly (6 red candles, huge) Stoch and RSI oversold and MACD not yet (it still seems to have room)...but TF day seems have already reversed or almost ....

1 · Reply

Shagg85 Jan. 30 at 3:53 PM

$NUVB pretty sure and hope 5.12 was the number for the gap down. Hopefully that was the bottom. Let’s get er

2 · Reply

Gabriel_DS Jan. 30 at 3:23 PM

$NUVB

0 · Reply

JanetBSmellin Jan. 30 at 2:12 PM

$NUVB Formimg a base $4.50-5.50 won’t be so bad. Wish I wouldn’t have started buying again at $7.50, but oh well.

0 · Reply

Shagg85 Jan. 30 at 1:30 PM

$NUVB let’s get this.

0 · Reply

JuggernautRaider Jan. 29 at 11:12 PM

$NUVB pipeline features a potential BIC gliomas asset and whatever else Hung is working on 🧪

0 · Reply

Bio_Invest101 Jan. 29 at 8:06 PM

$NUVB Bain Capital report Hung did such marvelous Anheart deal in 2024 so he knows where to look in China https://www.bain.com/insights/pharmaceuticals-m-and-a-report-2026/

0 · Reply

Frida_m Jan. 29 at 5:43 PM

$NUVB it feels like a bottom very cheap at this point I expect $40 per share in 2 years if not more

0 · Reply

marti837 Jan. 29 at 4:38 PM

$NUVB Someone is still leaving. Yes, these sales are not going as well as we would like, it's disappointing. But we are optimistic.

1 · Reply

Market Cap	1.80B
Revenue (ttm)	7.87M
Net Income (ttm)	-567.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,216.52%
Debt to Equity Ratio	0.16

Volume	5,998,200
Avg Vol	6,537,288
Day's Range	N/A - N/A
Shares Out	342.83M
Stochastic %K	69%
Beta	1.54
Analysts	Strong Sell
Price Target	$12.11